Intended Use

AlcoChange is a Digital therapeutic intended to reduce alcohol use and maintain abstinence in individuals with established alcohol-related liver disease (ArLD)

Indications for Use

AlcoChange is intended to provide behavioral therapy based on CyberLiver Behaviour Change (CBC) Model that is designed from the blend of principles from Various behaviour change theories in the design of  Digital Behaviour Change Techniques (DBCTs), Digital Behaviour Change  Interventions (DBCI’s). Personalised Motifications (motivational messages and interactions) are designed following the FRAMES model, consisting of Feedback, Responsibility, Advise, Menu for change, Empathy, and enhancing Self-efficacy.

AlcoChange, as an adjunct to a contingency management system, for patients 18 years of age and older who are currently enrolled in  outpatient treatment under the supervision of a clinician. AlcoChange is indicated as 90  days or 180 days prescription-only treatment for patients with Alcohol-Related Liver Disease. It is intended to increase abstinence and increase retention in the outpatient treatment program.  

It is intended to:

increase abstinence and increase retention in the outpatient treatment program,

and increase retention in the outpatient treatment program.

Please refer this link for Instructions of use